DXCOVER Ltd., a UK biotech company based in Glasgow, Scotland, has announced the launch of its US headquarters will be in Nashville, Tennessee. The move reflects DXCOVER’s commitment to commercializing its PANAROMIC™ cancer test in the world’s biggest life sciences market.
The new facilities will allow the company to forge partnerships with local biotech and healthcare organizations, advance local manufacturing of its innovative infrared spectroscopy platform and serve as a research and development hub aimed at extending DXCOVER’s leadership in cancer diagnostics innovation.
The State of Tennessee’s Representative in the UK & Ireland, Adam Breeze, said: “This project was possible thanks to the teamwork and efforts of our partners at the Nashville Area Chamber of Commerce and Williamson, Inc. in Franklin, where the new arrival will be based. DXCOVER is at the forefront of using AI for cancer detection, so given Tennessee’s health-tech and growing AI credentials, this is a perfect fit and exactly the kind of innovation-led FDI the state is looking to land. It will serve as a beacon for other European life science companies looking to expand into the US.”
Quoting DXCOVER’s CEO and Co-founder Matthew J. Baker, Ph.D.: “The launch of our US headquarters in Nashville, TN represents a major value-building milestone for us as we accelerate our mission to make early cancer detection accessible everywhere. Nashville is well known for its dynamic business environment in the healthcare field and we look forward to collaborating with research institutes, health organizations, and biotech start-ups to promote precision medicine and enhance early cancer detection solution access. Organizations such as Life Science Tennessee and BioTN are vital to the enhancement of life sciences innovation, and DXCOVER is eager to be an active member of this growing scientific community.”
Photos / Logo: © DXCOVER Ltd.
More Posts
Weidmüller Group Bolsters U.S. Manufacturing with $16.4m Expansion in Virginia, adding over 100 jobs
